These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6537910)

  • 1. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
    Zenebergh A; Baurain R; Trouet A
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of N,N-dimethyl daunorubicin and N,N-dimethyl adriamycin.
    Egorin MJ; Clawson RE; Ross LA; Bachur NR
    Cancer Res; 1980 Jun; 40(6):1928-33. PubMed ID: 7371027
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytofluorescence localization of anthracycline antibiotics.
    Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
    Cancer Res; 1980 Dec; 40(12):4669-76. PubMed ID: 6934029
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.
    Huybrechts M; Trouet A
    Cancer Chemother Pharmacol; 1980; 5(2):79-82. PubMed ID: 7471318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular pharmocodynamics of several anthrocycline antibiotics.
    Bachur NR; Steele M; Meriwether WD; Hildebrand RC
    J Med Chem; 1976 May; 19(5):651-4. PubMed ID: 1271407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
    Baurain R; Masquelier M; Deprez-De Campeneere D; Trouet A
    J Med Chem; 1980 Nov; 23(11):1171-4. PubMed ID: 7452666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on L1210 leukemia cells.
    Sorace RA; Sheid B
    Cancer Treat Rep; 1979 Jan; 63(1):43-51. PubMed ID: 421232
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular accumulation and disposition of aclacinomycin A.
    Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
    Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.
    Chervinsky DS; Wang JJ
    J Med; 1976; 7(1):63-79. PubMed ID: 1064679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
    Ganapathi R; Grabowski D
    Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
    Seeber S; Loth H; Crooke ST
    J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
    Hjelle JT; Baurain R; Masquelier M; Trouet A
    J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus.
    Kiyomiya K; Matsuo S; Kurebe M
    Life Sci; 1998; 62(20):1853-60. PubMed ID: 9600327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
    Meriwether WD; Bachur NR
    Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.